Bruno Chauffert

23.3k total citations · 7 hit papers
232 papers, 15.0k citations indexed

About

Bruno Chauffert is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Bruno Chauffert has authored 232 papers receiving a total of 15.0k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 69 papers in Pulmonary and Respiratory Medicine and 52 papers in Molecular Biology. Recurrent topics in Bruno Chauffert's work include Intraperitoneal and Appendiceal Malignancies (26 papers), Hepatocellular Carcinoma Treatment and Prognosis (23 papers) and Colorectal Cancer Treatments and Studies (21 papers). Bruno Chauffert is often cited by papers focused on Intraperitoneal and Appendiceal Malignancies (26 papers), Hepatocellular Carcinoma Treatment and Prognosis (23 papers) and Colorectal Cancer Treatments and Studies (21 papers). Bruno Chauffert collaborates with scholars based in France, United States and Switzerland. Bruno Chauffert's co-authors include François Ghiringhelli, Éric Solary, François Martin, Olivier Bouché, Marc Ychou, Thierry Conroy, Michel Ducreux, C. Montoto-Grillot, Pierre Michel and Jean‐Luc Raoul and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Bruno Chauffert

226 papers receiving 14.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

2011 5.5k citations Olivier Bouché, Bruno Chauffert et al. profile →
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

2006 968 citations François Ghiringhelli, Sylvain Ladoire et al. profile →
CD4⁺CD25⁺ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

2004 706 citations François Ghiringhelli, Nicolas Larmonier et al. European Journal of Immunology profile →
Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4 + CD25 + regulatory T cell proliferation

2005 588 citations François Ghiringhelli, S. Roux et al. The Journal of Experimental Medicine profile →
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

2008 501 citations Bruno Chauffert, F. Mornex et al. Annals of Oncology profile →
Iron‐dependent cell death of hepatocellular carcinoma cells exposed to sorafenib

2013 474 citations Jean‐Claude Barbare, Bruno Chauffert et al. profile →
The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells

2014 315 citations Jean‐Claude Barbare, Bruno Chauffert et al. Cancer Letters profile →

Peers

Countries citing papers authored by Bruno Chauffert

Since Specialization

Citations

This map shows the geographic impact of Bruno Chauffert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruno Chauffert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruno Chauffert more than expected).

Fields of papers citing papers by Bruno Chauffert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruno Chauffert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruno Chauffert. The network helps show where Bruno Chauffert may publish in the future.

Co-authorship network of co-authors of Bruno Chauffert

This figure shows the co-authorship network connecting the top 25 collaborators of Bruno Chauffert. A scholar is included among the top collaborators of Bruno Chauffert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruno Chauffert. Bruno Chauffert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma 2023 ·SHILAP Revista de lepidopterología ·Bruno Chauffert, Yuedan Zhou, (unknown), (unknown), (unknown), (unknown), (unknown), Ali A. Youssef, (unknown)	2
2	Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma 2021 ·Pharmaceuticals ·Nelly Étienne-Selloum, (unknown), (unknown), Mathieu Boone, Henri Sevestre, Stéphanie Trudel, Pascal Caillet, Alexandre Coutté, C. Desenclos, Jean‐Marc Constans, Sophie Martin, Laurence Choulier, Bruno Chauffert, Monique Dontenwill	5
3	Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results 2020 ·Quality of Life Research ·Caroline Mollévi, (unknown), C. Bourgier, Thierry Conroy, Bruno Chauffert, Mohamed Hebbar, William Jacot, Béata Juzyna, Hélène de Forges, Sophie Gourgou, Franck Bonnetain, Célia Touraine, Amélie Anota	10
4	Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma 2018 ·BMC Cancer ·(unknown), (unknown), (unknown), (unknown), Christophe Attencourt, Alexandre Coutté, Mathieu Boone, Henri Sevestre, Antoine Galmiche, Brigitte Gubler, Bruno Chauffert, Stéphanie Trudel	5
5	New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma 2014 ·Cancer Letters ·Antoine Galmiche, Bruno Chauffert, Jean‐Claude Barbare	74
6	Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study 2010 ·Anti-Cancer Drugs ·(unknown), Boris Guiu, Jean–Pierre Cercueil, Bruno Chauffert, Sylvain Ladoire, François Ghiringhelli	18
7	Prise en charge des adénocarcinomes de la jonction œsogastrique résécables : quel traitement périopératoire ? 2008 ·Cancer/Radiothérapie ·G. Créhange, Franck Bonnetain, Bruno Chauffert, Paul Rat, Laurent Bedenne, P. Maingon	6
8	Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d’une étude multicentrique de l’Anocef 2008 ·Revue Neurologique ·Séverine Guiu, Sophie Taillibert, Olivier Chinot, Luc Taillandier, Jérôme Honnorat, Pierre‐Yves Dietrich, (unknown), J.-S. Guillamo, Boris Guiu, (unknown), (unknown), Anne C. M. Thiébaut, Stéphanie Cartalat‐Carel, (unknown), P. Fumoleau, Annick Desjardins, Khê Hoang‐Xuan, Bruno Chauffert	39
9	Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study breakdown → 2008 ·Annals of Oncology ·Bruno Chauffert, F. Mornex, (unknown), P. Rougier, C. Mariette, Olivier Bouché, J.-F. Bosset, Thomas Aparicio, Laurent Mineur, A. Azzedine, Pascal Hammel, J Butel, Noël Stremsdoerfer, P. Maingon, Laurent Bedenne	501
10	Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer 2007 ·The Breast ·Laure Favier, Nicolás Isambert, Sylvie Zanetta, Emmanuelle Ferrant, F. Mayer, Bruno Chauffert, P. Fumoleau, (unknown), (unknown), Bruno Coudert	6
11	High Intra-abdominal Pressure Enhances the Penetration and Antitumor Effect of Intraperitoneal Cisplatin on Experimental Peritoneal Carcinomatosis 2006 ·Annals of Surgery ·(unknown), (unknown), Guy Magnin, (unknown), Philippe Moretto, M.D. Ynsa, (unknown), C. Drogoul, Michel Simonet, L. Benoît, Patrick Rat, Bruno Chauffert	134
12	Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4 + CD25 + regulatory T cell proliferation breakdown → 2005 ·The Journal of Experimental Medicine ·François Ghiringhelli, (unknown), S. Roux, Arnaud Parcellier, E. Schmitt, Éric Solary, Guido Kroemer, François Martin, Bruno Chauffert, Laurence Zitvogel	588
13	Preventing Lymphedema and Morbidity With an Omentum Flap After Ilioinguinal Lymph Node Dissection 2005 ·Annals of Surgical Oncology ·L. Benoît, Christophe Boichot, N. Cheynel, Laurent Arnould, Bruno Chauffert, Jean Cuisenier, J. Fraisse	43
14	CD4⁺CD25⁺ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative breakdown → 2004 ·European Journal of Immunology ·François Ghiringhelli, Nicolas Larmonier, E. Schmitt, Arnaud Parcellier, Dominique Cathelin, Carmen Garrido, Bruno Chauffert, Éric Solary, Bernard Bonnotte, François Martin	706
15	Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives 2003 ·Surgical Oncology Clinics of North America ·Bruno Chauffert, (unknown), (unknown), C. Duvillard, (unknown), Francis Bichat, Patrick Rat, Philippe Genne, L. Benoît	20
16	Identification of Tumor-Infiltrating Macrophages as the Killers of Tumor Cells After Immunization in a Rat Model System 2001 ·The Journal of Immunology ·Bernard Bonnotte, Nicolas Larmonier, Nathalie Favre, Annie Fromentin, Monique Moutet, Monique Martin, Sandeep Gurbuxani, Éric Solary, Bruno Chauffert, François Martin	61
17	Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma 2001 ·Anti-Cancer Drugs ·(unknown), Jean–Pierre Cercueil, Philippe Fauré, (unknown), Nicolás Isambert, (unknown), F. Cognet, D. Krausé, Laurent Bedenne, Bruno Chauffert	32
18	HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. 1997 ·PubMed ·Carmen Garrido, (unknown), Annie Fromentin, Arlette Hammann, André-Patrick Arrigo, Bruno Chauffert, Patrick Mehlen	208
19	Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells 1994 ·British Journal of Cancer ·Mahfoud Assem, Sylvie Bonvalot, (unknown), Carmen Garrido, Marie‐Thérèse Dimanche‐Boitrel, Philippe Genne, (unknown), Denis Caillot, Bruno Chauffert	16
20	Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM 1991 ·Cancer ·Éric Solary, (unknown), Bruno Chauffert, (unknown), Denis Caillot, Monique Dumas, Henri Guy	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact